Overview

A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease

Status:
RECRUITING

Trial end date:
2041-04-01

Target enrollment:

Participant gender:

Summary

This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.

Phase:

PHASE1

Details

Lead Sponsor:

Synthekine